-
1
-
-
59749095702
-
The burden of respiratory synytial virus infectionin young children
-
Breese C, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al. The burden of respiratory synytial virus infectionin young children. N Engl J Med 2009; 360: 588-8.
-
(2009)
N Engl J Med
, vol.360
, pp. 588-588
-
-
Breese, C.1
Weinberg, G.A.2
Iwane, M.K.3
Blumkin, A.K.4
Edwards, K.M.5
Staat, M.A.6
-
2
-
-
0028946637
-
Current approaches to the development of vaccinesagainst disease caused by respiratory syncytial virus (RSV) andparainfluenza virus (PIV). A meeting report of the WHOProgramme for Vaccine Development
-
Crowe JE Jr. Current approaches to the development of vaccinesagainst disease caused by respiratory syncytial virus (RSV) andparainfluenza virus (PIV). A meeting report of the WHOProgramme for Vaccine Development. Vaccine 1995; 13: 415-21.
-
(1995)
Vaccine
, vol.13
, pp. 415-421
-
-
Crowe Jr, J.E.1
-
3
-
-
77951101124
-
Review of palivizumab in the prophylaxis ofrespiratory synchytial virus (RSV) in high risk infants
-
Mejias A, Ramilo O. Review of palivizumab in the prophylaxis ofrespiratory synchytial virus (RSV) in high risk infants. Biologics 2008; 2: 433-9.
-
(2008)
Biologics
, vol.2
, pp. 433-439
-
-
Mejias, A.1
Ramilo, O.2
-
4
-
-
0347320936
-
Revised indications for theuse of palivizumab and respiratory syncytial virus immune globulinintravenous for the prevention of respiratory syncytial virusinfections
-
American Academy of Pediatrics Committee on Infectious Diseasesand Committee on Fetus and Newborn
-
American Academy of Pediatrics Committee on Infectious Diseasesand Committee on Fetus and Newborn. Revised indications for theuse of palivizumab and respiratory syncytial virus immune globulinintravenous for the prevention of respiratory syncytial virusinfections. Pediatrics 2003; 112: 1442-6.
-
(2003)
Pediatrics
, vol.112
, pp. 1442-1446
-
-
-
8
-
-
0025391838
-
From the National Institute of Allergy and InfectiousDiseases and the World Health Organization. Respiratory syncytialand parainfluenza viruses
-
Heilman CA
-
Heilman CA. From the National Institute of Allergy and InfectiousDiseases and the World Health Organization. Respiratory syncytialand parainfluenza viruses. J Infect Dis 1990; 161: 402-6.
-
(1990)
J Infect Dis
, vol.161
, pp. 402-406
-
-
-
9
-
-
0022589125
-
Risk of primaryinfection and reinfection with respiratory syncytial virus
-
Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primaryinfection and reinfection with respiratory syncytial virus. Am J DisChild 1986; 140: 543-6.
-
(1986)
Am J DisChild
, vol.140
, pp. 543-546
-
-
Glezen, W.P.1
Taber, L.H.2
Frank, A.L.3
Kasel, J.A.4
-
10
-
-
0032696770
-
Bronchiolitis-associated hospitalizations among US children,1980-1996
-
Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, AndersonLJ. Bronchiolitis-associated hospitalizations among US children,1980-1996. JAMA 1999; 282:1440-6.
-
(1999)
JAMA
, vol.282
, pp. 1440-1446
-
-
Shay, D.K.1
Holman, R.C.2
Newman, R.D.3
Liu, L.L.4
Stout, J.W.5
Anderson, L.J.6
-
11
-
-
0035168864
-
Bronchiolitis - associated mortality and estimates of respiratorysyncytial virus associated-deaths among US children. 1979-1997
-
Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson LJ.Bronchiolitis - associated mortality and estimates of respiratorysyncytial virus associated-deaths among US children. 1979-1997. JInfect Dis 2001; 183: 16-22.
-
(2001)
JInfect Dis
, vol.183
, pp. 16-22
-
-
Shay, D.K.1
Holman, R.C.2
Roosevelt, G.E.3
Clarke, M.J.4
Anderson, L.J.5
-
12
-
-
0031748527
-
Respiratorysyncytial virus infection in tropical and developing countries
-
Weher MW, Mulholland EK, Greenwood BM. Respiratorysyncytial virus infection in tropical and developing countries. TropMed Int Health 1988; 3: 268-80.
-
(1988)
TropMed Int Health
, vol.3
, pp. 268-280
-
-
Weher, M.W.1
Mulholland, E.K.2
Greenwood, B.M.3
-
13
-
-
0033554244
-
Respiratory syncytial virus in early life and risk ofwheeze and allergy by age 13 years
-
Stein RT, Sherrill D, Morgan WJ, Holberg CJ, Halonen M, TaussigLM, et al. Respiratory syncytial virus in early life and risk ofwheeze and allergy by age 13 years. Lancet 1999; 354: 541-5.
-
(1999)
Lancet
, vol.354
, pp. 541-545
-
-
Stein, R.T.1
Sherrill, D.2
Morgan, W.J.3
Holberg, C.J.4
Halonen, M.5
Taussig, L.M.6
-
14
-
-
0033836306
-
The role of viral infections in the naturalhistory of asthma
-
Germ JE, Busse WW. The role of viral infections in the naturalhistory of asthma. J Allergy Clin Immunol 2000; 106: 201-12.
-
(2000)
J Allergy Clin Immunol
, vol.106
, pp. 201-212
-
-
Germ, J.E.1
Busse, W.W.2
-
16
-
-
0029737098
-
Respiratory syncytial virus is an important cause ofcommunity-acquired lower respiratory infection among hospitalizedadults
-
Dowell SF, Anderson LJ, Gary HE Jr, Erdman DD, Plouffe JF, FileTM Jr, et al. Respiratory syncytial virus is an important cause ofcommunity-acquired lower respiratory infection among hospitalizedadults. J Infect Dis 1996; 174: 456-62.
-
(1996)
J Infect Dis
, vol.174
, pp. 456-462
-
-
Dowell, S.F.1
Anderson, L.J.2
Gary Jr., H.E.3
Erdman, D.D.4
Plouffe, J.F.5
Film Jr, T.M.6
-
17
-
-
0033949819
-
Respiratory syncytial virus infection amonghospitalized adults
-
Falsey AR, Walsh EE. Respiratory syncytial virus infection amonghospitalized adults. Clin Microbiol Rev 2000; 13: 371-84.
-
(2000)
Clin Microbiol Rev
, vol.13
, pp. 371-384
-
-
Falsey, A.R.1
Walsh, E.E.2
-
19
-
-
35348828518
-
Understanding respiratorysyncytial virus (RSV) vaccine-enhanced disease
-
Castilow EM, Olson MR, Varga SM. Understanding respiratorysyncytial virus (RSV) vaccine-enhanced disease. Immunol Res2007; 39: 225-39.
-
(2007)
Immunol Res
, vol.39
, pp. 225-239
-
-
Castilow, E.M.1
Olson, M.R.2
Varga, S.M.3
-
20
-
-
33846270721
-
Prospects for developingvaccines without this complication
-
Little-van der Hurk SD, Mapletoft JW, Arsic N, Nolan JK.Immunopathology of RSV infection
-
Little-van der Hurk SD, Mapletoft JW, Arsic N, Nolan JK.Immunopathology of RSV infection: Prospects for developingvaccines without this complication. Rev Med Virol 2007; 17: 5-34.
-
(2007)
Rev Med Virol
, vol.17
, pp. 5-34
-
-
-
21
-
-
0023275087
-
Demonstration thatglycoprotein G. is the attachment protein of respiratory syncytialvirus
-
Levine S, Klaiber-Franco R, Paradiso PR. Demonstration thatglycoprotein G is the attachment protein of respiratory syncytialvirus. J Gen Virol 1987; 68 (Pt 9): 2521-4.
-
(1987)
J Gen Virol
, vol.68
, Issue.Pt 9
, pp. 2521-2524
-
-
Levine, S.1
Klaiber-Franco, R.2
Paradiso, P.R.3
-
22
-
-
0023427601
-
Antigenic relatedness between glycoproteins ofhuman respiratory syncytial virus subgroups A and B. Evaluation ofthe contributions of F and G glycoproteins to immunity
-
Johnson PR Jr, Olmsted RA, Prince GA, Murphy BR, Alling DW,Walsh EE, et al. Antigenic relatedness between glycoproteins ofhuman respiratory syncytial virus subgroups A and B. Evaluation ofthe contributions of F and G glycoproteins to immunity. J Virol1987; 61: 3163-6.
-
(1987)
J Virol
, vol.61
, pp. 3163-3166
-
-
Johnson Jr, P.R.1
Olmsted, R.A.2
Prince, G.A.3
Murphy, B.R.4
-
23
-
-
0036838764
-
Respiratory syncytial virus induced activationof nuclear factor -B in the lung involves alveolar macrophages andToll-like receptor 4-dependent pathways
-
Haeberle HA, Takizawa R, Casola A, Brasier AR, Dieterich HJ,Van Rooijen N, et al. Respiratory syncytial virus induced activationof nuclear factor -B in the lung involves alveolar macrophages andToll-like receptor 4-dependent pathways. J Infect Dis 2002;186:1199-206.
-
(2002)
J Infect Dis
, vol.186
, pp. 1199-1206
-
-
Haeberle, H.A.1
Takizawa, R.2
Casola, A.3
Brasier, A.R.4
Dieterich, H.J.5
van Rooijen, N.6
-
24
-
-
53849132415
-
Pulmonary immunity and immuno-pathology: Lessons from respiratory syncytial virus
-
Olson MR, Varga SM. Pulmonary immunity and immuno-pathology: lessons from respiratory syncytial virus. Expert RevVaccines 2008; 7: 1239-55.
-
(2008)
Expert RevVaccines
, vol.7
, pp. 1239-1255
-
-
Olson, M.R.1
Varga, S.M.2
-
25
-
-
34547124330
-
Function of therespiratory synchytial vrus small hydrophobic protein
-
Fuentes S, Tran KC, Luthra P, Teng MN, He B. Function of therespiratory synchytial vrus small hydrophobic protein. J Virol 2007;81: 8361-6.
-
(2007)
J Virol
, vol.81
, pp. 8361-8366
-
-
Fuentes, S.1
Tran, K.C.2
Luthra, P.3
Teng, M.N.4
He, B.5
-
26
-
-
0036229487
-
Respiratory syncytial virus (RSV)nonstructural (NS) proteins as host range determinants: A chimericbovine RSV with NS genes from human RSV is attenuated ininterferon-competent bovine cells
-
Bossert B, Conzelmann KK. Respiratory syncytial virus (RSV)nonstructural (NS) proteins as host range determinants: A chimericbovine RSV with NS genes from human RSV is attenuated ininterferon-competent bovine cells. J Virol 2002; 76: 4287-93.
-
(2002)
J Virol
, vol.76
, pp. 4287-4293
-
-
Bossert, B.1
Conzelmann, K.K.2
-
27
-
-
1842483896
-
Suppression ofthe induction of alpha, beta, and lambda interferons by the NS1 andNS2 proteins of human respiratory syncytial virus in humanepithelial cells and macrophages
-
Erratum2005, 6705-9
-
Spann KM, Tran KC, Chi B, Rabin RL, Collins PL. Suppression ofthe induction of alpha, beta, and lambda interferons by the NS1 andNS2 proteins of human respiratory syncytial virus in humanepithelial cells and macrophages. J Virol 2004; 78: 4363-9 (Erratum2005; 78: 6705-9).
-
(2004)
J Virol
, vol.78
, pp. 4363-4369
-
-
Spann, K.M.1
Tran, K.C.2
Chi, B.3
Rabin, R.L.4
Collins, P.L.5
-
28
-
-
33846815515
-
Nonstructural proteins of respiratory syncytialvirus suppress premature apoptosis by an NF- B-dependent,interferon-independent mechanism and facilitate virus growth
-
Bitko V, Shulyayeva O, Mazumder B, Musiyenko A, RamaswamyM, Look DC, et al. Nonstructural proteins of respiratory syncytialvirus suppress premature apoptosis by an NF- B-dependent,interferon-independent mechanism and facilitate virus growth. JVirol 2007; 81: 1786-95.
-
(2007)
JVirol
, vol.81
, pp. 1786-1795
-
-
Bitko, V.1
Shulyayeva, O.2
Mazumder, B.3
Musiyenko, A.4
Ramaswamy, M.5
Look, D.C.6
-
29
-
-
0014495164
-
Firstevaluation of a respiratory syncytial virus vaccine and a trivalentparainfluenza virus vaccine in a pediatric population
-
Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH. Firstevaluation of a respiratory syncytial virus vaccine and a trivalentparainfluenza virus vaccine in a pediatric population. Am JEpidemiol 1969; 89: 449-63.
-
(1969)
Am JEpidemiol
, vol.89
, pp. 449-463
-
-
Chin, J.1
Magoffin, R.L.2
Shearer, L.A.3
Schieble, J.H.4
Lennette, E.H.5
-
30
-
-
0014495251
-
Respiratory syncytial virus disease in infants despite prioradministration of antigenic inactivated vaccine
-
Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, JensenK, et al. Respiratory syncytial virus disease in infants despite prioradministration of antigenic inactivated vaccine. Am J Epidemiol1969; 89: 422-34.
-
(1969)
Am J Epidemiol
, vol.89
, pp. 422-434
-
-
Kim, H.W.1
Canchola, J.G.2
Brandt, C.D.3
Pyles, G.4
Chanock, R.M.5
-
31
-
-
0014493282
-
An epidemiological study of altered clinical reactivity torespiratory syncytial (RS) virus infection in children previouslyvaccinated with an inactivated RS virus vaccine
-
Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiological study of altered clinical reactivity torespiratory syncytial (RS) virus infection in children previouslyvaccinated with an inactivated RS virus vaccine. Am J Epidemiol1969; 89: 405-21.
-
(1969)
Am J Epidemiol
, vol.89
, pp. 405-421
-
-
Kapikian, A.Z.1
Mitchell, R.H.2
Chanock, R.M.3
Shvedoff, R.A.4
Stewart, C.E.5
-
32
-
-
22244473286
-
Immune responses and diseaseenhancement during respiratory syncytial virus infection
-
Openshaw PJM, Tregoning JS. Immune responses and diseaseenhancement during respiratory syncytial virus infection. ClinMicrobiol Rev 2005; 18: 541-55.
-
(2005)
ClinMicrobiol Rev
, vol.18
, pp. 541-555
-
-
Openshaw, P.J.M.1
Tregoning, J.S.2
-
33
-
-
0022555443
-
Dissociation between serum neutralizing andglycoprotein antibody responses of infants and children whoreceived inactivated respiratory sycytial virus vaccine
-
Murphy BR, Prince GA, Walsh EE, Kim HW, Parrott RH,Hemming VG, et al. Dissociation between serum neutralizing andglycoprotein antibody responses of infants and children whoreceived inactivated respiratory sycytial virus vaccine. J ClinMicrobiol 1986; 24: 197-202.
-
(1986)
J ClinMicrobiol
, vol.24
, pp. 197-202
-
-
Murphy, B.R.1
Prince, G.A.2
Walsh, E.E.3
Kim, H.W.4
Parrott, R.H.5
Hemming, V.G.6
-
34
-
-
40149098584
-
Human and bovine respiratorysyncytial virus vaccine research and development
-
Meyer G, Deplance M, Schelcher F. Human and bovine respiratorysyncytial virus vaccine research and development. Comp ImmunolMicrobiol Infect Dis 2008; 31: 191-225.
-
(2008)
Comp ImmunolMicrobiol Infect Dis
, vol.31
, pp. 191-225
-
-
Meyer, G.1
Deplance, M.2
Schelcher, F.3
-
35
-
-
33749256261
-
Respiratory syncytial virus diseasemechanisms implicated by human, animal model, and in vitro datafacilitate vaccine strategies and new therapeutics
-
Moore ML, Peebles RS Jr. Respiratory syncytial virus diseasemechanisms implicated by human, animal model, and in vitro datafacilitate vaccine strategies and new therapeutics. Pharmacol Ther2006; 112: 405-24.
-
(2006)
Pharmacol Ther
, vol.112
, pp. 405-424
-
-
Moore, M.L.1
Peebles Jr., R.S.2
-
36
-
-
0347479195
-
Progress in the development of respiratorysyncytial virus and parainfluenza virus vaccines
-
Durbin AP, Karron RA. Progress in the development of respiratorysyncytial virus and parainfluenza virus vaccines. Clin Infect Dis2003; 37: 1668-77.
-
(2003)
Clin Infect Dis
, vol.37
, pp. 1668-1677
-
-
Durbin, A.P.1
Karron, R.A.2
-
37
-
-
1842684459
-
IL-4utilizes an alternative receptor to drive apoptosis of Th1 cells andskews neonatal immunity toward Th2
-
Li L, Lee HH, Bell JJ, Gregg RK, Ellis JS, Gessner A, et al. IL-4utilizes an alternative receptor to drive apoptosis of Th1 cells andskews neonatal immunity toward Th2. Immunity 2004; 20: 429-40.
-
(2004)
Immunity
, vol.20
, pp. 429-440
-
-
Li, L.1
Lee, H.H.2
Bell, J.J.3
Gregg, R.K.4
Ellis, J.S.5
Gessner, A.6
-
38
-
-
0035815511
-
Pathogenesis ofRSV Lower respiratory tract infection: Implications for vaccinedevelopment
-
Brandenburg AH, Neijens HJ, Osterhaus ADME. Pathogenesis ofRSV Lower respiratory tract infection: implications for vaccinedevelopment. Vaccine 2001; 19: 2769-82.
-
(2001)
Vaccine
, vol.19
, pp. 2769-2782
-
-
Brandenburg, A.H.1
Neijens, H.J.2
Osterhaus, A.D.M.E.3
-
39
-
-
0020572023
-
Antibodies torespiratory syncytial virus polypeptides and their significance inhuman infection
-
Ward KA, Lambden PR, Ogilvie MM, Watt PJ. Antibodies torespiratory syncytial virus polypeptides and their significance inhuman infection. J Gen Virol 1983; 64: 1867-76.
-
(1983)
J Gen Virol
, vol.64
, pp. 1867-1876
-
-
Ward, K.A.1
Lambden, P.R.2
Ogilvie, M.M.3
Watt, P.J.4
-
40
-
-
0027384670
-
Prophylactic administration of respiratory syncytial virusimmune globulin to high risk infants and young children. Therespiratory synchytial virus immune globulin study group
-
Groothuis JR, Simoes EA, Levin MJ, Hall CB, Long CE, RodriguezWJ, et al. Prophylactic administration of respiratory syncytial virusimmune globulin to high risk infants and young children. Therespiratory synchytial virus immune globulin study group. N Engl JMed 1993; 329: 1524-30.
-
(1993)
N Engl JMed
, vol.329
, pp. 1524-1530
-
-
Groothuis, J.R.1
Simoes, E.A.2
Levin, M.J.3
Hall, C.B.4
Long, C.E.5
Rodriguez, W.J.6
-
41
-
-
1342329509
-
Respiratory syncytial virus: The virus, the disease and theimmune response
-
Olgra PL. Respiratory syncytial virus: The virus, the disease and theimmune response. Paediatr Respir Rev 2004; 5(Suppl A): S119-S126.
-
(2004)
Paediatr Respir Rev
, vol.5
, Issue.SUPPL. A
-
-
Olgra, P.L.1
-
42
-
-
38449084342
-
Cd8 T Cells inhibit respiratory syncytialvirus (RSV) vaccine-enhanced disease
-
Olson MR, Varga SM. CD8 T cells inhibit respiratory syncytialvirus (RSV) vaccine-enhanced disease. J Immunol 2007; 179:5415-24.
-
(2007)
J Immunol
, vol.179
, pp. 5415-5424
-
-
Olson, M.R.1
Varga, S.M.2
-
43
-
-
71849118589
-
The number of RSV-specificmemory CD8 T cells in the lung is critical for their ability to inhibitrespiratory syncytial virus (RSV) vaccine-enhanced pulmonaryeosinophilia
-
Olson MR, Hartwig SM, Varga SM. The number of RSV-specificmemory CD8 T cells in the lung is critical for their ability to inhibitrespiratory syncytial virus (RSV) vaccine-enhanced pulmonaryeosinophilia. J Immunol 2008; 181: 7958-68.
-
(2008)
J Immunol
, vol.181
, pp. 7958-7968
-
-
Olson, M.R.1
Hartwig, S.M.2
Varga, S.M.3
-
44
-
-
0028107250
-
Distinct types of lungdisease caused by functional subsets of antiviral T cells
-
Alwan WH, Kozlowska WJ, Openshaw PJ. Distinct types of lungdisease caused by functional subsets of antiviral T cells. J Exp Med1994; 179: 81-9.
-
(1994)
J Exp Med
, vol.179
, pp. 81-89
-
-
Alwan, W.H.1
Kozlowska, W.J.2
Openshaw, P.J.3
-
45
-
-
0026460748
-
Pulmonary histopathology induced byrespiratory syncytial virus (RSV) challenge of formalin-inactivatedRSV-immunized BALB/c mice is abrogated by depletion of CD4+T cells
-
Connors M, Kulkarni AB, Firestone CY, Holmes KL, Morse HC3rd, Sotnikov AV, et al. Pulmonary histopathology induced byrespiratory syncytial virus (RSV) challenge of formalin-inactivatedRSV-immunized BALB/c mice is abrogated by depletion of CD4+T cells. J Virol 1992; 66: 7444-51.
-
(1992)
J Virol
, vol.66
, pp. 7444-7451
-
-
Connors, M.1
Kulkarni, A.B.2
Firestone, C.Y.3
Holmes, K.L.4
Morse 3rd, H.C.5
Sotnikov, A.V.6
-
46
-
-
0034749998
-
Infection is mediated by a discrete oligoclonal subset ofantigen-specific CD4 (+) T cells
-
Varga SM, Wang X, WElsch RM, Braciale TJ. Immunopathologyin RSV infection is mediated by a discrete oligoclonal subset ofantigen-specific CD4 (+) T cells. Immunity 2001; 15: 637-46.
-
(2001)
Immunity
, vol.15
, pp. 637-646
-
-
Varga, S.M.1
Wang, X.2
Welsch, R.M.3
Braciale, T.J.4
Immunopathologyin, R.S.V.5
-
47
-
-
45749110581
-
RSV 2007: Recent advancesin respiratory syncytial virus research
-
Stevens WW, Falsey AR, Braciale TJ. RSV 2007: Recent advancesin respiratory syncytial virus research. Viral Immunol 2008; 21:133-40.
-
(2008)
Viral Immunol
, vol.21
, pp. 133-140
-
-
Stevens, W.W.1
Falsey, A.R.2
Braciale, T.J.3
-
48
-
-
55849152459
-
Overcoming T cell mediated immuno-pathology to achieve safe RSV vaccination
-
Castilow EM, Varga S. Overcoming T cell mediated immuno-pathology to achieve safe RSV vaccination. Future Virol 2008; 3:445-54.
-
(2008)
Future Virol
, vol.3
, pp. 445-454
-
-
Castilow, E.M.1
Varga, S.2
-
49
-
-
0028241420
-
HildrethS. Respiratory syncytial virus specific cell mediated immuneresponses after vaccination with a purified fusion protein subunitvaccine
-
Welliver RC, Tristram DA, Batt K, Sun M, Hogerman D, HildrethS. Respiratory syncytial virus specific cell mediated immuneresponses after vaccination with a purified fusion protein subunitvaccine. J Infect Dis 1994; 170: 425-8.
-
(1994)
J Infect Dis
, vol.170
, pp. 425-428
-
-
Welliver, R.C.1
Tristram, D.A.2
Batt, K.3
Sun, M.4
Hogerman, D.5
-
50
-
-
0030250348
-
Safety and immunogenicity of a respiratorysyncytial virus subunit vaccine (PFP-2) in ambulatory adults overage 60
-
Falsey AR, Walsh EE. Safety and immunogenicity of a respiratorysyncytial virus subunit vaccine (PFP-2) in ambulatory adults overage 60. Vaccine 1996; 14:1214-8.
-
(1996)
Vaccine
, vol.14
, pp. 1214-1218
-
-
Falsey, A.R.1
Walsh, E.E.2
-
51
-
-
0030031491
-
Purified fusion protein vaccine protects against lowerrespiratory tract illness during respiratory syncytial virus season inchildren with cystic fibrosis
-
Piedra PE, Grace S, Jewell A, Spinelli S, Bunting D, HogermanDA, et al. Purified fusion protein vaccine protects against lowerrespiratory tract illness during respiratory syncytial virus season inchildren with cystic fibrosis. Pediatr Infect Dis J 1996; 15: 23-31.
-
(1996)
Pediatr Infect Dis J
, vol.15
, pp. 23-31
-
-
Piedra, P.E.1
Grace, S.2
Jewell, A.3
Spinelli, S.4
Bunting, D.5
Hogerman, D.A.6
-
52
-
-
0030793204
-
Safety and immunogenicity of a respiratorysyncytial virus subunit vaccine (PFP-2) in the institutionalizedelderly
-
Falsey AR, Walsh EE. Safety and immunogenicity of a respiratorysyncytial virus subunit vaccine (PFP-2) in the institutionalizedelderly. Vaccine 1997; 15: 1130-2.
-
(1997)
Vaccine
, vol.15
, pp. 1130-1132
-
-
Falsey, A.R.1
Walsh, E.E.2
-
53
-
-
0031906484
-
Safety and immunogenicity of a purified F protein respiratorysyncytial virus (PFP-2) vaccine in seropositive children withbronchopulmonary dysplasia
-
Groothuis JR, King SJ, Hogerman DA, Paradiso PR, Simoes EA.Safety and immunogenicity of a purified F protein respiratorysyncytial virus (PFP-2) vaccine in seropositive children withbronchopulmonary dysplasia. J Infect Dis 1998; 177: 467-9.
-
(1998)
J Infect Dis
, vol.177
, pp. 467-469
-
-
Groothuis, J.R.1
King, S.J.2
Hogerman, D.A.3
Paradiso, P.R.4
Simoes, E.A.5
-
54
-
-
0027463527
-
HImmunogenicity and safety of respiratory syncytialvirus subunit vaccine in seropositive children 18-36 months
-
Tristram DA, Welliver RC, Mohar CK, Hogerman DA, HildrethSW, Paradiso P. Immunogenicity and safety of respiratory syncytialvirus subunit vaccine in seropositive children 18-36 months. JInfect Dis 1993; 167:191-5.
-
(1993)
JInfect Dis
, vol.167
, pp. 191-195
-
-
Tristram, D.A.1
Welliver, R.C.2
Mohar, C.K.3
Hogerman, D.A.4
Hildreth, S.W.5
Paradiso, P.6
-
55
-
-
0028288689
-
Second year surveillance of respiratory syncytial virus (RSV) Fprotein subunit vaccine, PFP-1: Evaluation of antibody persistenceand possible disease enhancement
-
Tristram DA, Welliver RC, Hogerman DA, Hildreth SW, ParadisoP. Second year surveillance of respiratory syncytial virus (RSV) Fprotein subunit vaccine, PFP-1: Evaluation of antibody persistenceand possible disease enhancement. Vaccine 1994; 12: 551-6.
-
(1994)
Vaccine
, vol.12
, pp. 551-556
-
-
Tristram, D.A.1
Welliver, R.C.2
Hogerman, D.A.3
Hildreth, S.W.4
Paradiso, P.5
-
56
-
-
0028017725
-
Safety and Immunogenicity of A Subunitrespiratory Syncytial Virus Vaccine In Children 24-48 Months Old
-
Paradiso PR, Hildreth SW, Hogerman DA, Speelman DJ, LewinEB, Oren J, et al. Safety and immunogenicity of a subunitrespiratory syncytial virus vaccine in children 24-48 months old.Pediatr Infect Dis J 1994; 13: 792-8.
-
(1994)
Pediatr Infect Dis J
, vol.13
, pp. 792-798
-
-
Paradiso, P.R.1
Hildreth, S.W.2
Hogerman, D.A.3
Speelman, D.J.4
Lewin, E.B.5
Oren, J.6
-
57
-
-
0031894642
-
Sequential annual administration of purified fusion proteinvaccine against respiratory syncytial virus in children with cysticfibrosis
-
Piedra PA, Grace S, Jewell A, Spinelli S, Hogerman DA, MalinoskiF, et al. Sequential annual administration of purified fusion proteinvaccine against respiratory syncytial virus in children with cysticfibrosis. Pediatr Infect Dis J 1998; 17: 217-24.
-
(1998)
Pediatr Infect Dis J
, vol.17
, pp. 217-224
-
-
Piedra, P.A.1
Grace, S.2
Jewell, A.3
Spinelli, S.4
Hogerman, D.A.5
Malinoski, F.6
-
58
-
-
0038384095
-
Safety and immunogenicity ofrespiratory syncytial virus purified fusion protein-2 vaccine inpregnant women
-
Munoz FM, Piedra PA, Glezen WP. Safety and immunogenicity ofrespiratory syncytial virus purified fusion protein-2 vaccine inpregnant women. Vaccine 2003; 21: 3465-7.
-
(2003)
Vaccine
, vol.21
, pp. 3465-3467
-
-
Munoz, F.M.1
Piedra, P.A.2
Glezen, W.P.3
-
59
-
-
69749092449
-
A dose-ranging study of a subunit Respiratory SyncytialVirus subtype A vaccine with and without aluminium phosphateadjuvantation in adults > or =65 years of age
-
Langley JM, Sales V, McGeer A, Guasparini R, Predy G, MeekisonW, et al. A dose-ranging study of a subunit Respiratory SyncytialVirus subtype A vaccine with and without aluminium phosphateadjuvantation in adults > or =65 years of age. Vaccine 2009; 27:5913-9.
-
(2009)
Vaccine
, vol.27
, pp. 5913-5919
-
-
Langley, J.M.1
Sales, V.2
McGeer, A.3
Guasparini, R.4
Predy, G.5
Meekison, W.6
-
60
-
-
0035852331
-
Respiratorysyncytial virus vaccine: A systematic overview with emphasis onrespiratory syncytial virus subunit vaccines
-
Simoes EA, Tan DH, Ohlsson A, Sales V, Wang EE. Respiratorysyncytial virus vaccine: A systematic overview with emphasis onrespiratory syncytial virus subunit vaccines. Vaccine 2001; 20: 954-60.
-
(2001)
Vaccine
, vol.20
, pp. 954-960
-
-
Simoes, E.A.1
Tan, D.H.2
Ohlsson, A.3
Sales, V.4
Wang, E.E.5
-
61
-
-
0034080129
-
Serum neutralizing antibodytiters of seropositive chimpanzees immunized with vaccines co-formulated with natural fusion and attachment proteins ofrespiratory syncytial virus
-
Hancock GE, Smith JD, Heers KM. Serum neutralizing antibodytiters of seropositive chimpanzees immunized with vaccines co-formulated with natural fusion and attachment proteins ofrespiratory syncytial virus. J Infect Dis 2000; 181:1768-71.
-
(2000)
J Infect Dis
, vol.181
, pp. 1768-1771
-
-
Hancock, G.E.1
Smith, J.D.2
Heers, K.M.3
-
62
-
-
0026084919
-
Vaccination of cotton rats with a chimeric FGglycoprotein of human respiratory syncytial virus induces minimalpulmonary pathology on challenge
-
Wathen MW, Kakuk TJ, Brideau RJ, Hausknecht EC, Cole SL,Zaya RM. Vaccination of cotton rats with a chimeric FGglycoprotein of human respiratory syncytial virus induces minimalpulmonary pathology on challenge. J Infect Dis 1991; 163: 477-82.
-
(1991)
J Infect Dis
, vol.163
, pp. 477-482
-
-
Wathen, M.W.1
Kakuk, T.J.2
Brideau, R.J.3
Hausknecht, E.C.4
Cole, S.L.5
Zaya, R.M.6
-
63
-
-
0026581303
-
Cotton rats previously immunized with a chimericRSV FG glycoprotein develop enhanced pulmonary pathologywhen infected with RSV, a phenomenon not encountered followingimmunization with vaccinia-RSV recombinants or RSV
-
Connors M, Collins PL, Firestone CY, Sotnikov AV, Cotton rats previously immunized with a chimericRSV FG glycoprotein develop enhanced pulmonary pathologywhen infected with RSV, a phenomenon not encountered followingimmunization with vaccinia-RSV recombinants or RSV. Vaccine1992; 10: 475-84.
-
(1992)
Vaccine
, vol.10
, pp. 475-484
-
-
Connors, M.1
Collins, P.L.2
Firestone, C.Y.3
Sotnikov, A.V.4
Waitze, A.5
Davis, A.R.6
-
64
-
-
0031848862
-
Respiratory syncytial virus vaccines
-
Dudas R, Karron RA. Respiratory syncytial virus vaccines. ClinMicrobiol Rev 1998; 11: 430-9.
-
(1998)
ClinMicrobiol Rev
, vol.11
, pp. 430-439
-
-
Dudas, R.1
Karron, R.A.2
-
65
-
-
0030968130
-
Induction of protective immunity in rodents by vaccinationwith a prokaryotically expressed recombinant fusion proteincontaining a respiratory syncytial virus G protein fragment
-
Power UF, Plotnicky-Gilquin H, Huss T, Robert A, Trudel M, Ståhl S, et al. Induction of protective immunity in rodents by vaccinationwith a prokaryotically expressed recombinant fusion proteincontaining a respiratory syncytial virus G protein fragment.Virology 1997; 230: 155-66.
-
(1997)
Virology
, vol.230
, pp. 155-166
-
-
Power, U.F.1
Plotnicky-Gilquin, H.2
Huss, T.3
Robert, A.4
Trudel, M.5
Ståhl, S.6
-
66
-
-
0030820061
-
Protective immunity against respiratorysyncytial virus in early life after murine maternal or neonatalvaccination with the recombinant G fusion protein BBG2Na
-
Brandt C, Power UF, Plotnicky-Gilquin H, Huss T, Nguyen T,Lambert PH, et al. Protective immunity against respiratorysyncytial virus in early life after murine maternal or neonatalvaccination with the recombinant G fusion protein BBG2Na. JInfect Dis 1997; 176: 884-91.
-
(1997)
JInfect Dis
, vol.176
, pp. 884-891
-
-
Brandt, C.1
Power, U.F.2
Plotnicky-Gilquin, H.3
Huss, T.4
Nguyen, T.5
Lambert, P.H.6
-
67
-
-
0030744003
-
Challenge of BALB/c Mice With Respiratory Syncytial Virusdoes Not Enhance the Th2 Pathway Induced After Immunization Witha Recombinant G Fusion Protein, BBG2Na, In Aluminum Hydroxide
-
Corvaia N, Tournier P, Nguyen TN, Haeuw JF, Power UF, Binz H,et al. Challenge of BALB/c mice with respiratory syncytial virusdoes not enhance the Th2 pathway induced after immunization witha recombinant G Fusion protein, BBG2Na, in aluminum hydroxide.J Infect Dis 1997; 176: 560-9.
-
(1997)
J Infect Dis
, vol.176
, pp. 560-569
-
-
Corvaia, N.1
Tournier, P.2
Nguyen, T.N.3
Haeuw, J.F.4
Power, U.F.5
Binz, H.6
-
68
-
-
34447581209
-
Neonatal human autologousdentritic cells pulsed with recombinant protein antigen prime thegeneration of non polarized CD4 T-cell effectors
-
Matthews NC, Power UF, Reen DJ. Neonatal human autologousdentritic cells pulsed with recombinant protein antigen prime thegeneration of non polarized CD4 T-cell effectors. Int Immunol2007; 19: 703-12.
-
(2007)
Int Immunol
, vol.19
, pp. 703-712
-
-
Matthews, N.C.1
Power, U.F.2
Reen, D.J.3
-
69
-
-
0033602701
-
Absence of lung immunopathology followingrespiratory syncytial virus (RSV) challenge in mice immunizedwith a recombinant RSV G fragment
-
Plotnicky-Gilquin H, Huss T, Aubry JP, Haeuw JF, Beck A,Bonnefoy JY, et al. Absence of lung immunopathology followingrespiratory syncytial virus (RSV) challenge in mice immunizedwith a recombinant RSV G fragment. Virology 1999; 258: 128-40.
-
(1999)
Virology
, vol.258
, pp. 128-140
-
-
Plotnicky-Gilquin, H.1
Huss, T.2
Aubry, J.P.3
Haeuw, J.F.4
Beck, A.5
Bonnefoy, J.Y.6
-
70
-
-
0034212718
-
Influence of live respiratory syncytial viruspriming on the immune response generated by a recombinantvaccine candidate, BBG2Na
-
Goestch L, Plotnicky-Gilquin H, Champion T, Beck A, Haeuw JF,Nguyen T, et al. Influence of live respiratory syncytial viruspriming on the immune response generated by a recombinantvaccine candidate, BBG2Na. Vaccine 2000; 18: 2648-55.
-
(2000)
Vaccine
, vol.18
, pp. 2648-2655
-
-
Goestch, L.1
Plotnicky-Gilquin, H.2
Champion, T.3
Beck, A.4
Haeuw, J.F.5
Nguyen, T.6
-
71
-
-
0034212397
-
Influence of administration dose and route on theimmunogenicity and protective efficacy of BBG2Na, a recombinantrespiratory syncytial virus subunit vaccine candidate
-
Goetsch L, Plotnicky- Gilquin H, Champion T, Beck A, Corvaïa N,Stâhl S, et al. Influence of administration dose and route on theimmunogenicity and protective efficacy of BBG2Na, a recombinantrespiratory syncytial virus subunit vaccine candidate. Vaccine 2000;18: 2735-42.
-
(2000)
Vaccine
, vol.18
, pp. 2735-2742
-
-
Goetsch, L.1
Plotnicky-Gilquin, H.2
Champion, T.3
Beck, A.4
Corvaïa, N.5
Stâhl, S.6
-
72
-
-
0035577405
-
Safety and immunogenenicity of a novelrecombinant subunit respiratory syncytial virus vaccine (BBG2Na)in healthy young adults
-
Power UF, Nguyen TN, Rietveld E, de Swart RL, Groen J,Osterhaus AD, et al. Safety and immunogenenicity of a novelrecombinant subunit respiratory syncytial virus vaccine (BBG2Na)in healthy young adults. J Infect Dis 2001; 184: 1456-60.
-
(2001)
J Infect Dis
, vol.184
, pp. 1456-1460
-
-
Power, U.F.1
Nguyen, T.N.2
Rietveld, E.3
de Swart, R.L.4
Groen, J.5
Osterhaus, A.D.6
-
73
-
-
0036928450
-
Passive transfer of serum antibodiesinduced by BBG2Na, a subunit vaccine, in the elderly protectsSCID mouse lungs against respiratory syncytial virus challenge
-
Plotnicky-Gilquin H, Cyblat-Chanal D, Goetsch L, Lacheny C,Libon C, Champion T, et al. Passive transfer of serum antibodiesinduced by BBG2Na, a subunit vaccine, in the elderly protectsSCID mouse lungs against respiratory syncytial virus challenge.Virology 2002; 303: 130-7.
-
(2002)
Virology
, vol.303
, pp. 130-137
-
-
Plotnicky-Gilquin, H.1
Cyblat-Chanal, D.2
Goetsch, L.3
Lacheny, C.4
Libon, C.5
Champion, T.6
-
74
-
-
34748908970
-
Long lastingbalanced immunity and protective efficacy against respiratorysyncytial virus in mice induced by a recombinant protein G1F/M2
-
Zeng R, Qi X, Gong W, Mei X, Wei L, Ma C, et al. Long lastingbalanced immunity and protective efficacy against respiratorysyncytial virus in mice induced by a recombinant protein G1F/M2.Vaccine 2007; 25: 7422-8.
-
(2007)
Vaccine
, vol.25
, pp. 7422-7428
-
-
Zeng, R.1
Qi, X.2
Gong, W.3
Mei, X.4
Wei, L.5
Ma, C.6
-
75
-
-
46149087536
-
Sub-nucleocapsid nanoparticles: A nasal vaccineagainst respiratory syncytial virus
-
Roux X, Dubuquoy C, Durand G, Tran-Tolla TL, Castagné N,Bernard J, et al. Sub-nucleocapsid nanoparticles: A nasal vaccineagainst respiratory syncytial virus. PloS One 2008; 3: e1766.
-
(2008)
PloS One
, vol.e1766
, pp. 3
-
-
Roux, X.1
Dubuquoy, C.2
Durand, G.3
Tran-Tolla, T.L.4
Castagné, N.5
Bernard, J.6
-
76
-
-
0030060742
-
Effective immunization with live attenuatedinfluenza A virus can be achieved in early infancy
-
Clements ML, Makhene MK, Karron RA, Murphy BR, SteinhoffMC, Subbarao K, et al. Effective immunization with live attenuatedinfluenza A virus can be achieved in early infancy. J Infect Dis1996; 173: 44-51.
-
(1996)
J Infect Dis
, vol.173
, pp. 44-51
-
-
Clements, M.L.1
Makhene, M.K.2
Karron, R.A.3
Murphy, B.R.4
Steinhoff, M.C.5
Subbarao, K.6
-
77
-
-
0032147238
-
Vaccinestrategies to overcome maternal antibody mediated inhibition ofmeasles vaccine
-
Osterhaus A, van Amerongen G, van Binnendijk R. Vaccinestrategies to overcome maternal antibody mediated inhibition ofmeasles vaccine. Vaccine 1998; 16: 1479-81.
-
(1998)
Vaccine
, vol.16
, pp. 1479-1481
-
-
Osterhaus, A.1
van Amerongen, G.2
van Binnendijk, R.3
-
80
-
-
0030657620
-
Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccinesin chimpanzees and in human adults, infants and children
-
Karron RA, Wright PF, Crowe JEJr. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccinesin chimpanzees and in human adults, infants and children. J InfectDis 1997; 176:1428-36.
-
(1997)
J InfectDis
, vol.176
, pp. 1428-1436
-
-
Karron, R.A.1
Wright, P.F.2
Crowe Jr, J.E.3
-
81
-
-
0033997580
-
Evaluation of the live attenuated cpts 248/404RSV vaccine in combination with a subunit RSV vaccine (PFP-2)in healthy young and older adults
-
Gonzalez IM, Karron RA, Eichelberger M, Walsh EE, DelagarzaVW, Bennett R, et al. Evaluation of the live attenuated cpts 248/404RSV vaccine in combination with a subunit RSV vaccine (PFP-2)in healthy young and older adults. Vaccine 2000; 18: 1763-72.
-
(2000)
Vaccine
, vol.18
, pp. 1763-1772
-
-
Gonzalez, I.M.1
Karron, R.A.2
Eichelberger, M.3
Walsh, E.E.4
Delagarza, V.W.5
Bennett, R.6
-
82
-
-
0033791293
-
Evaluation of a live, cold passaged, temperature -sensitive, respiratory syncytial virus vaccine candidate in infancy
-
Wright PF, Karron RA, Belshe RB, Thompson J, Crowe JE Jr,Boyce TG, et al. Evaluation of a live, cold passaged, temperature -sensitive, respiratory syncytial virus vaccine candidate in infancy. JInfect Dis 2000; 182: 1331-42.
-
(2000)
JInfect Dis
, vol.182
, pp. 1331-1342
-
-
Wright, P.F.1
Karron, R.A.2
Belshe, R.B.3
Thompson, J.4
Crowe Jr, J.E.5
Boyce, T.G.6
-
83
-
-
4644282211
-
Parainfluenza virus type 3 expressing in native or solublefusion (F) protein of respiratory syncytial virus (RSV) confersprotection from RSV infection in African green monkeys
-
Tang RS, MacPhail M, Schickli JH, Kaur J, Robinson CL, LawlorHA, et al. Parainfluenza virus type 3 expressing in native or solublefusion (F) protein of respiratory syncytial virus (RSV) confersprotection from RSV infection in African green monkeys. J Virol2004; 78: 11198-207.
-
(2004)
J Virol
, vol.78
, pp. 11198-207
-
-
Tang, R.S.1
Macphail, M.2
Schickli, J.H.3
Kaur, J.4
Robinson, C.L.5
Lawlor, H.A.6
-
84
-
-
55749098115
-
Development of a PIV-vectored RSV vaccine:Preclinical evaluation of safety, toxicity, and enhanced disease andinitial clinical testing in healthy adults
-
Tang RS, Spaete RR, Thompson MW, MacPhail M, Guzzetta JM,Ryan PC, et al. Development of a PIV-vectored RSV vaccine:Preclinical evaluation of safety, toxicity, and enhanced disease andinitial clinical testing in healthy adults. Vaccine 2008; 26: 6373-82.
-
(2008)
Vaccine
, vol.26
, pp. 6373-6382
-
-
Tang, R.S.1
Spaete, R.R.2
Thompson, M.W.3
Macphail, M.4
Guzzetta, J.M.5
Ryan, P.C.6
-
85
-
-
20144370691
-
Identification of a recombinant live attenuated respiratorysyncytial virus vaccine candidate that is highly attenuated in infants
-
Karron RA, Wright PF, Belshe RB, Thumar B, Casey R, NewmanF, et al. Identification of a recombinant live attenuated respiratorysyncytial virus vaccine candidate that is highly attenuated in infants.J Infect Dis 2005; 191: 1093-104.
-
(2005)
J Infect Dis
, vol.191
, pp. 1093-1104
-
-
Karron, R.A.1
Wright, P.F.2
Belshe, R.B.3
Thumar, B.4
Casey, R.5
Newman, F.6
-
86
-
-
32044433987
-
The interferon antagonist NS2 protein of respiratory syncytialvirus is an important virulence determinant for humans
-
Wright PF, Karron RA, Madhi SA, Treanor JJ, King JC, O'Shea A,et al. The interferon antagonist NS2 protein of respiratory syncytialvirus is an important virulence determinant for humans. J Infect Dis2006; 15: 193: 573-81.
-
(2006)
J Infect Dis
, vol.15
, Issue.193
, pp. 573-581
-
-
Wright, P.F.1
Karron, R.A.2
Madhi, S.A.3
Treanor, J.J.4
King, J.C.5
O'Shea, A.6
-
87
-
-
0033997580
-
Evaluation of the live attenuated cpts248/404 RSV vaccine in combination with a subunit RSV vaccine(PFP-2) in healthy young and older adults
-
Gonzalez IM, Karron RA, Eichelberger M, Walsh EE, DelagarzaVW, Bennett R, et al. Evaluation of the live attenuated cpts248/404 RSV vaccine in combination with a subunit RSV vaccine(PFP-2) in healthy young and older adults. Vaccine 2000; 18: 1763-72.
-
(2000)
Vaccine
, vol.18
, pp. 1763-1772
-
-
Gonzalez, I.M.1
Karron, R.A.2
Eichelberger, M.3
Walsh, E.E.4
Delagarza, V.W.5
Bennett, R.6
-
88
-
-
0037484129
-
Mechanisms by which maternal antibodies influenceinfant vaccine responses: Review of hypotheses and definition ofmain determinants
-
Siegrist CA. Mechanisms by which maternal antibodies influenceinfant vaccine responses: review of hypotheses and definition ofmain determinants. Vaccine 2003; 21: 3406-12
-
(2003)
Vaccine
, vol.21
, pp. 3406-3412
-
-
Siegrist, C.A.1
-
89
-
-
0030711687
-
DNA immunization of neonatesinduces immunity despite the presence of maternal antibody
-
Manickan E, Yu Z, Rouse BT. DNA immunization of neonatesinduces immunity despite the presence of maternal antibody. J ClinInvest 1997; 100: 2371-5.
-
(1997)
J ClinInvest
, vol.100
, pp. 2371-2375
-
-
Manickan, E.1
Yu, Z.2
Rouse, B.T.3
-
90
-
-
18344410538
-
Protection against respiratory syncytial virus infection byDNA immunization
-
Li X, Sambhara S, Li CX, Ewasyshyn M, Parrington M, Caterini J,et al. Protection against respiratory syncytial virus infection byDNA immunization. J Exp Med 1998; 188: 681-8.
-
(1998)
J Exp Med
, vol.188
, pp. 681-688
-
-
Li, X.1
Sambhara, S.2
Li, C.X.3
Ewasyshyn, M.4
Parrington, M.5
Caterini, J.6
-
91
-
-
0034732137
-
Plasmid DNA encoding the respiratory sycytial virus G protein is apromising vaccine candidate
-
Li X, Sambhara S, Li CX, Switzer I, Cates G, James O, et al.Plasmid DNA encoding the respiratory sycytial virus G protein is apromising vaccine candidate. Virology 2000; 269: 54-65.
-
(2000)
Virology
, vol.269
, pp. 54-65
-
-
Li, X.1
Sambhara, S.2
Li, C.X.3
Switzer, I.4
Cates, G.5
James, O.6
-
92
-
-
0033804606
-
DNA encoding the attachment (G) or fusion (F) proteinor respiratory syncytial virus induces protection in the absence ofpulmonary inflammation
-
Bembridge GP, Rodriguez N, Beato GR, Nicolson C, Melero JA,Taylor G. DNA encoding the attachment (G) or fusion (F) proteinor respiratory syncytial virus induces protection in the absence ofpulmonary inflammation. J Gen Virol 2000; 81: 2519-23.
-
(2000)
J Gen Virol
, vol.81
, pp. 2519-2523
-
-
Bembridge, G.P.1
Rodriguez, N.2
Beato, G.R.3
Nicolson, C.4
Melero, J.A.5
Taylor, G.6
-
93
-
-
3042764814
-
Advances in respiratory syncytialvirus vaccine development
-
Kneyber MCJ, Kimpen JLL. Advances in respiratory syncytialvirus vaccine development. Cur Opin Invest Drugs 2004; 5: 163-70.
-
(2004)
Cur Opin Invest Drugs
, vol.5
, pp. 163-170
-
-
Kneyber, M.C.J.1
Kimpen, J.L.L.2
-
94
-
-
0034624098
-
Respiratory syncytial virus infection of gene gunvaccinated mice induces Th2 driven pulmonary eosinophilia even inthe absence of sensitisation to the fusion (F) or attachment (G)protein
-
Bembridge GP, Rodriguez N, Beato GR, Nicolson C, Melero JA,Taylor G. Respiratory syncytial virus infection of gene gunvaccinated mice induces Th2 driven pulmonary eosinophilia even inthe absence of sensitisation to the fusion (F) or attachment (G)protein. Vaccine 2000; 19: 1038-46.
-
(2000)
Vaccine
, vol.19
, pp. 1038-1046
-
-
Bembridge, G.P.1
Rodriguez, N.2
Beato, G.R.3
Nicolson, C.4
Melero, J.A.5
Taylor, G.6
-
95
-
-
5444257335
-
Gene gun DNA vaccination aggravates respiratory syncytial virusinduced pneumonitis
-
Bartholdy C, Olszewska W, Stryhn A, Thomsen AR, Openshaw PJ.Gene gun DNA vaccination aggravates respiratory syncytial virusinduced pneumonitis. J Gen Virol 2004; 85: 3017-26.
-
(2004)
J Gen Virol
, vol.85
, pp. 3017-3026
-
-
Bartholdy, C.1
Olszewska, W.2
Stryhn, A.3
Thomsen, A.R.4
Openshaw, P.J.5
-
96
-
-
0037471402
-
Nasal delivery of chitosan-DNA plasmid expressing epitopes ofrespiratory syncytial virus (RSV) induces protective CTL responsesin BALB/c mice
-
Iqbal M, Lin W, Jabbal-Gill I, Davis SS, Steward MW, Illum L.Nasal delivery of chitosan-DNA plasmid expressing epitopes ofrespiratory syncytial virus (RSV) induces protective CTL responsesin BALB/c mice. Vaccine 2003; 21:1478-85.
-
(2003)
Vaccine
, vol.21
, pp. 1478-1485
-
-
Iqbal, M.1
Lin, W.2
Jabbal-Gill, I.3
Davis, S.S.4
Steward, M.W.5
Illum, L.6
-
98
-
-
34548490545
-
Oralrespiratory syncytial virus (RSV) DNA vaccine expressing RSV Fprotein delivered by attenuated Salmonella typhimurium
-
Xie C, He JS, Zhang M, Xue SL, Wu Q, Ding XT, et al. Oralrespiratory syncytial virus (RSV) DNA vaccine expressing RSV Fprotein delivered by attenuated Salmonella typhimurium. HumGene Ther 2007; 18: 746-52.
-
(2007)
HumGene Ther
, vol.18
, pp. 746-752
-
-
Xie, C.1
He, J.S.2
Zhang, M.3
Xue, S.L.4
Wu, Q.5
Ding, X.T.6
-
99
-
-
34648840508
-
Immunogenicity andefficacy of codon optimized DNA vaccines encoding the F-proteinof respiratory syncytial virus
-
Ternette N, Tippler B, Uberla K, Grunwald T. Immunogenicity andefficacy of codon optimized DNA vaccines encoding the F-proteinof respiratory syncytial virus. Vaccine 2007; 25: 7271-9.
-
(2007)
Vaccine
, vol.25
, pp. 7271-7279
-
-
Ternette, N.1
Tippler, B.2
Uberla, K.3
Grunwald, T.4
-
100
-
-
38349066207
-
Polylactide-co-glycolide (PLG) microparticlesmodify the immune response to DNA vaccination
-
Helson R, Olszewska W, Singh M, Megede JZ, Melero JA,O'Hagan D, et al. Polylactide-co-glycolide (PLG) microparticlesmodify the immune response to DNA vaccination. Vaccine 2008;26: 753-61.
-
(2008)
Vaccine
, vol.26
, pp. 753-761
-
-
Helson, R.1
Olszewska, W.2
Singh, M.3
Megede, J.Z.4
Melero, J.A.5
O'Hagan, D.6
-
101
-
-
58149242781
-
Enhancement of mucosal and cellularimmune response in mice by vaccination with respiratory syncytialvirus DNA encapsulated with transfersome
-
Xu J, Ding Y, Yang Y. Enhancement of mucosal and cellularimmune response in mice by vaccination with respiratory syncytialvirus DNA encapsulated with transfersome. Viral Immunol 2008;21: 483-9.
-
(2008)
Viral Immunol
, vol.21
, pp. 483-489
-
-
Xu, J.1
Ding, Y.2
Yang, Y.3
-
102
-
-
39749187575
-
Single intranasal immunizationwith recombinant adenovirus-based vaccine induces protectiveimmunity against respiratory syncytial virus infection
-
Yu JR, Kim S, Lee JB, Chang J. Single intranasal immunizationwith recombinant adenovirus-based vaccine induces protectiveimmunity against respiratory syncytial virus infection. J Virol 2008;82: 2350-7.
-
(2008)
J Virol
, vol.82
, pp. 2350-2357
-
-
Yu, J.R.1
Kim, S.2
Lee, J.B.3
Chang, J.4
-
103
-
-
62949177862
-
Intranasalimmunization with a replication-deficient adenoviral vectorexpressing the fusion glycoprotein of respiratory syncytial viruselicits protective immunity in BALB/c mice
-
Fu Y, He J, Zheng X, Wu Q, Zhang M, Wang X, et al. Intranasalimmunization with a replication-deficient adenoviral vectorexpressing the fusion glycoprotein of respiratory syncytial viruselicits protective immunity in BALB/c mice. Biochem Biophys ResCommun 2009; 381: 528-32.
-
(2009)
Biochem Biophys ResCommun
, vol.381
, pp. 528-532
-
-
Fu, Y.1
He, J.2
Zheng, X.3
Wu, Q.4
Zhang, M.5
Wang, X.6
-
104
-
-
68549132243
-
Immunogenic properties of RSV-B1 fusion (F) protein gene-encoding recombinant adenoviruses
-
Shao HY, Yu SL, Sia C, Chen Y, Chitra E, Chen IH, et al.Immunogenic properties of RSV-B1 fusion (F) protein gene-encoding recombinant adenoviruses. Vaccine 2009; 27: 5460-71.
-
(2009)
Vaccine
, vol.27
, pp. 5460-5471
-
-
Shao, H.Y.1
Yu, S.L.2
Sia, C.3
Chen, Y.4
Chitra, E.5
Chen, I.H.6
-
105
-
-
1242338194
-
Vaccination of infant macaques with arecombinant modified vaccinia virus Ankara expressing therespiratory syncytial virus F and G genes does not predispose forimmunopathology
-
de Waal L, Wyatt LS, Yüksel S, van Amerongen G, Moss B,Niesters HG, et al. Vaccination of infant macaques with arecombinant modified vaccinia virus Ankara expressing therespiratory syncytial virus F and G genes does not predispose forimmunopathology. Vaccine 2004; 22: 923-6.
-
(2004)
Vaccine
, vol.22
, pp. 923-926
-
-
de Waal, L.1
Wyatt, L.S.2
Yüksel, S.3
van Amerongen, G.4
Moss, B.5
Niesters, H.G.6
-
106
-
-
12844268178
-
The Immunomodulating Properties of Human Respiratorysyncytial Virus and Immunostimulating Complexes ContainingQuillaja Saponin Components QH-A, QH-C and ISCOPREP 703
-
Hu KF, Regner M, Siegrist CA, Lambert P, Chen M, BengtssonKL, et al. The immunomodulating properties of human respiratorysyncytial virus and immunostimulating complexes containingQuillaja saponin components QH-A, QH-C and ISCOPREP 703.FEMS Immunol Med Microbiol 2005; 43: 269-76.
-
(2005)
FEMS Immunol Med Microbiol
, vol.43
, pp. 269-276
-
-
Hu, K.F.1
Regner, M.2
Siegrist, C.A.3
Lambert, P.4
Chen, M.5
Bengtsson, K.L.6
-
107
-
-
0030887353
-
Adjuvants influence the quantitative and qualitative immuneresponse in BALB/c mice immunized with respiratory syncytialvirus FG subunit vaccine
-
Neuzil KM, Johnson JE, Tang YW, Prieels JP, Slaoui M, Gar N,et al. Adjuvants influence the quantitative and qualitative immuneresponse in BALB/c mice immunized with respiratory syncytialvirus FG subunit vaccine. Vaccine 1997; 15: 525-32.
-
(1997)
Vaccine
, vol.15
, pp. 525-532
-
-
Neuzil, K.M.1
Johnson, J.E.2
Tang, Y.W.3
Prieels, J.P.4
Slaoui, M.5
Gar, N.6
-
108
-
-
0034507382
-
QS-21 synergizes withrecombinant interleukin 12 to create a potent adjuvant formulationfor the fusion protein of respiratory syncytial virus
-
Hancock GE, Heers KM, Smith JD. QS-21 synergizes withrecombinant interleukin 12 to create a potent adjuvant formulationfor the fusion protein of respiratory syncytial virus. Viral Immunol2000; 13: 503-9.
-
(2000)
Viral Immunol
, vol.13
, pp. 503-509
-
-
Hancock, G.E.1
Heers, K.M.2
Smith, J.D.3
-
109
-
-
0034081441
-
CD40 ligand (CD154) enhances the Th1 and antibody responses to respiratorysyncytial virus in the BALB/c mouse
-
Tripp RA, Jones L, Anderson LJ, Brown MP. CD40 ligand (CD154) enhances the Th1 and antibody responses to respiratorysyncytial virus in the BALB/c mouse. J Immunol 2000; 164: 5913-21.
-
(2000)
J Immunol
, vol.164
, pp. 5913-5921
-
-
Tripp, R.A.1
Jones, L.2
Anderson, L.J.3
Brown, M.P.4
-
110
-
-
0035860575
-
CpG containing oligodeoxynucleotides are potentadjuvants for parenteral vaccination with the fusion (F) protein ofrespiratory syncytial virus (RSV)
-
Hancock GE, Heers KM, Smith JD, Scheuer CA, Ibraghimov AR,Pryharski KS. CpG containing oligodeoxynucleotides are potentadjuvants for parenteral vaccination with the fusion (F) protein ofrespiratory syncytial virus (RSV). Vaccine 2001; 19: 4874-82.
-
(2001)
Vaccine
, vol.19
, pp. 4874-4882
-
-
Hancock, G.E.1
Heers, K.M.2
Smith, J.D.3
Scheuer, C.A.4
Ibraghimov, A.R.5
Pryharski, K.S.6
-
111
-
-
0346817398
-
Adjuvants recognized by toll-like receptors inhibit the induction ofpolarized type 2 T cell responses by natural attachment (G) proteinof respiratory syncytial virus
-
Hancock GE, Heers KM, Pryharski KS, Smith JD, Tiberio L.Adjuvants recognized by toll-like receptors inhibit the induction ofpolarized type 2 T cell responses by natural attachment (G) proteinof respiratory syncytial virus. Vaccine 2003; 21: 4348-58.
-
(2003)
Vaccine
, vol.21
, pp. 4348-4358
-
-
Hancock, G.E.1
Heers, K.M.2
Pryharski, K.S.3
Smith, J.D.4
Tiberio, L.5
-
112
-
-
67349253124
-
TLR9agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapyduring primary RSV infection increases disease severity
-
Johnson TR, Rao S, Seder RA, Chen M, Graham BS. TLR9agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapyduring primary RSV infection increases disease severity. Vaccine2009; 27: 3045-52.
-
(2009)
Vaccine
, vol.27
, pp. 3045-3052
-
-
Johnson, T.R.1
Rao, S.2
Seder, R.A.3
Chen, M.4
Graham, B.S.5
-
113
-
-
0031902954
-
The immunostimulating complex (ISCOM) is anefficient mucosal delivery system for respiratory syncytial virus(RSV) envelope antigens inducing high local and systemic antibodyresponses
-
Hu KF, Elvander M, Merza M, Akerblom L, Brandenburg A,Morein B. The immunostimulating complex (ISCOM) is anefficient mucosal delivery system for respiratory syncytial virus(RSV) envelope antigens inducing high local and systemic antibodyresponses. Clin Exp Immunol 1998; 113: 235-43.
-
(1998)
Clin Exp Immunol
, vol.113
, pp. 235-243
-
-
Hu, K.F.1
Elvander, M.2
Merza, M.3
Akerblom, L.4
Brandenburg, A.5
Morein, B.6
-
116
-
-
77954036588
-
Combination vaccineagainst Streptococcus pneumoniae and respiratory syncytial virus(RSV)
-
Deschamps, M., Laferriere, C., Joseph, A. Combination vaccineagainst Streptococcus pneumoniae and respiratory syncytial virus(RSV). EP1927366A1 (2008).
-
(2008)
EP1927366A1
-
-
Deschamps, M.1
Laferriere, C.2
Joseph, A.3
-
118
-
-
77954037057
-
-
W.US2007110759
-
Sattentau, Q.J., Openshaw, P.J., Moghaddam, A.E., Olszewska, W.US2007110759 (2007).
-
(2007)
Olszewska
-
-
Sattentau, Q.J.1
Openshaw, P.J.2
Moghaddam, A.E.3
Olszewska, W.4
-
119
-
-
77954054430
-
-
US2006024797
-
Krempl, C.D., Collins, P.L., Murphy, B.R., Buchholz, U.,Whitehead, S.S. Respiratory syncytial virus vaccines expressingprotective antigens from promoter-proximal genes. US2006024797(2006).
-
(2006)
Respiratory Syncytial Virus Vaccines Expressingprotective Antigens From Promoter-proximal Genes
-
-
Krempl, C.D.1
Collins, P.L.2
Murphy, B.R.3
Buchholz, U.4
Whitehead, S.S.5
-
120
-
-
77954061215
-
-
Shenrong, J., Yunlin, W., Lianbing, L., Xiuling, J., Guang, L.Respiratory syncytial virus sub-units vaccine, preparation andapplication. CN101264323 (2008).
-
(2008)
Respiratory Syncytial Virus Sub-units Vaccine, Preparation Andapplication. CN101264323
-
-
Shenrong, J.1
Yunlin, W.2
Lianbing, L.3
Xiuling, J.4
Guang, L.5
-
121
-
-
77954039797
-
-
Buetow, D.E., Korban, S.S., Sandhu, J., Krasnyanski, S.F. Plant-derived vaccines against respiratory syncytial virus. US2005129704(2005).
-
(2005)
Plant-derived Vaccines Against Respiratory Syncytial Virus. US2005129704
-
-
Buetow, D.E.1
Korban, S.S.2
Sandhu, J.3
Krasnyanski, S.F.4
|